APHINITY
E902901
APHINITY is a large phase III clinical trial evaluating the benefit of adding pertuzumab to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| APHINITY canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074794 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: APHINITY Context triple: [APHINITY trial, acronym, APHINITY]
-
A.
Clearpoint
Clearpoint is a popular line of Paper Mate mechanical pencils known for their side-click advance mechanism and comfortable, ergonomic design.
-
B.
Phocus
Phocus is a minor figure in Greek mythology known primarily as a descendant of the Corinthian royal line.
-
C.
Wellin
Wellin is a small municipality and town located in the Luxembourg Province of Wallonia in southern Belgium.
-
D.
Daphni
Daphni is an area near Athens in Greece known for its historic monastery and its location along the ancient route between Athens and Eleusis.
-
E.
Modalys
Modalys is a sound synthesis and physical modeling software environment developed at IRCAM for creating and exploring complex virtual instruments and acoustic phenomena.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: APHINITY Target entity description: APHINITY is a large phase III clinical trial evaluating the benefit of adding pertuzumab to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
-
A.
Clearpoint
Clearpoint is a popular line of Paper Mate mechanical pencils known for their side-click advance mechanism and comfortable, ergonomic design.
-
B.
Phocus
Phocus is a minor figure in Greek mythology known primarily as a descendant of the Corinthian royal line.
-
C.
Wellin
Wellin is a small municipality and town located in the Luxembourg Province of Wallonia in southern Belgium.
-
D.
Daphni
Daphni is an area near Athens in Greece known for its historic monastery and its location along the ancient route between Athens and Eleusis.
-
E.
Modalys
Modalys is a sound synthesis and physical modeling software environment developed at IRCAM for creating and exploring complex virtual instruments and acoustic phenomena.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
adjuvant breast cancer trial
ⓘ
clinical trial ⓘ phase III clinical trial ⓘ randomized controlled trial ⓘ |
| acronymFor | Adjuvant Pertuzumab and Herceptin IN Initial TherapY of Breast Cancer NERFINISHED ⓘ |
| blinding | patients and investigators were blinded to pertuzumab vs placebo ⓘ |
| chemotherapyBackbone | anthracycline-based or non-anthracycline-based regimens ⓘ |
| collaborator |
BIG 4-11
ⓘ
Breast International Group NERFINISHED ⓘ NSABP B-52 / B-46-like groups NERFINISHED ⓘ National Surgical Adjuvant Breast and Bowel Project NERFINISHED ⓘ |
| controlArmTreatment | trastuzumab plus chemotherapy ⓘ |
| design |
double-blind
ⓘ
multicenter ⓘ placebo-controlled ⓘ |
| evaluatesDrug |
chemotherapy
ⓘ
pertuzumab NERFINISHED ⓘ trastuzumab NERFINISHED ⓘ |
| experimentalArmTreatment | pertuzumab plus trastuzumab plus chemotherapy ⓘ |
| firstAuthor | Gunter von Minckwitz NERFINISHED ⓘ |
| fullName | Adjuvant Pertuzumab and Herceptin IN Initial TherapY of Breast Cancer NERFINISHED ⓘ |
| geographicScope | international ⓘ |
| HER2StatusInclusion | HER2-positive ⓘ |
| hormoneReceptorStatusInclusion | hormone receptor–positive or hormone receptor–negative ⓘ |
| interventionDuration | 1 year of anti-HER2 therapy ⓘ |
| keyFinding |
addition of pertuzumab improved invasive disease-free survival in node-positive patients
ⓘ
benefit of pertuzumab was more pronounced in higher-risk subgroups such as node-positive disease ⓘ |
| population | patients with operable HER2-positive early breast cancer ⓘ |
| primaryAnalysisPublicationYear | 2017 GENERATED ⓘ |
| primaryEndpoint | invasive disease-free survival ⓘ |
| primaryObjective | to evaluate the benefit of adding pertuzumab to standard trastuzumab-based adjuvant therapy ⓘ |
| publicationVenue | New England Journal of Medicine NERFINISHED ⓘ |
| randomizationRatio | 1:1 ⓘ |
| regionOfEnrollment |
Asia
NERFINISHED
ⓘ
Europe NERFINISHED ⓘ North America NERFINISHED ⓘ South America NERFINISHED ⓘ |
| registration | ClinicalTrials.gov NCT01358877 NERFINISHED ⓘ |
| safetyFinding | cardiac safety profile was acceptable and similar between arms ⓘ |
| secondaryEndpoint |
cardiac safety
ⓘ
distant recurrence-free interval ⓘ overall survival ⓘ |
| sponsor |
F. Hoffmann-La Roche Ltd
NERFINISHED
ⓘ
Genentech NERFINISHED ⓘ |
| startYear | 2011 ⓘ |
| targetDisease |
HER2-positive early breast cancer
ⓘ
early-stage HER2-positive breast cancer ⓘ |
| therapeuticClassEvaluated | HER2-targeted monoclonal antibodies ⓘ |
| therapySetting | adjuvant therapy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: APHINITY Description of subject: APHINITY is a large phase III clinical trial evaluating the benefit of adding pertuzumab to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.